2 citations
,
December 2006 in “Lancet Oncology” This study found that 1 mg/day of finasteride significantly reduced serum PSA concentrations in men with androgenic alopecia aged 40–60 over 48 weeks, suggesting implications for prostate-cancer screening in this population.
February 2007 in “Journal watch” Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
October 2025 in “International Journal of Social health” This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.
March 2015 in “The Journal of Urology” This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.
September 2017 in “ics.org”
